- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01768923
Early RA Vascular Randomised Controlled Study
Effect of Treat-to-target Strategies Aiming at Remission Compared With Minimal Disease Activity on Arterial Stiffness in Early Rheumatoid Arthritis - a Randomised Controlled Study
To investigate the effect of two tight-control treatment strategies, aiming at 1) 2011 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) definition of remission compare with 2) minimal disease activity (Disease Activity Index in 28 joints [DAS28] <2.6), on arterial stiffness in early rheumatoid arthritis (RA) patients.
To compare the effect of two treatments on arterial stiffness in Early Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
One hundred RA patients with active disease (DAS28 >/=3.2), duration of symptoms less than 2 years, and are disease modifying anti-rheumatic drug naive will participate in this 5-year prospective, hospital-based, open-label, randomized, controlled trial.
All participants will receive 1-year tight-control treatment. One hundred patients will be randomly assigned to two arms. Treatment will be adjusted according to a standardized protocol every 3-monthly aiming at remission defined by the 2011 ACR/EULAR definition (Group 1, n=50, simplified disease activity score [SDAI] ≤3.3) or minimal disease activity (Group 2, n=50, DAS28<2.6). A follow up visit will be conducted at the 5th year to evulate long term effect on vascular outcomes between the two groups.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong, China
- Prince of Wales Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- fulfilled the 2010 ACR/EULAR classification criteria for RA
- have symptoms onset of less than 2 years
- have active disease (DAS28> 3.2)
- are positive for rheumatoid factor or anti-cyclic citrullinated protein antibodies
Exclusion Criteria:
- have a history of overt cardiovascular diseases
- are on aspirin, or HMG-CoA reductase inhibitors (statins) or angiotensin-converting-enzyme inhibitor (ACEI)
- have severe renal impairment defined as a glomerular filtration rate of less than 30 ml/min/1.73m2
- have been previously treated with tumor necrosis factor alpha (TNFa) inhibitors or other biological DMARDs
- on glucocorticoids at a dose >10mg/day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SDAI remission group
SDAI remission
|
SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)
|
Active Comparator: Minimal disease activity group
Minimal disease activity remission
|
Minimal disease activity group aims at minimal disease activity (DAS28<2.6)
(minimal disease activity group)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in PWV over 1-year of treatment
Time Frame: Baseline and 12 months
|
The change in PWV over 1-year of treatment
|
Baseline and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients achieve clinical remission
Time Frame: 12 months
|
The proportion of patients achieve clinical remission (SDAI</= 3.3 or DAS28<2.6) after 1-year treatment
|
12 months
|
The proportion of patients with a good response
Time Frame: 12 months
|
According to EULAR definition, good response is DAS28 < 3.2 and a fall in score from baseline by > 1.2
|
12 months
|
ACR 20, 50, 70 responses
Time Frame: 12 months
|
ACR 20, 50, 70 responses defined as at least 20%, 50%, 70% improvement in joint swelling and joint tenderness counts, and three of five other variables (i.e.
ESR or CRP, HAQ score, pain score and physicians' and patients' global assessments)
|
12 months
|
The change in Alx@75 over 1-year of treatment
Time Frame: Baseline and 12 months
|
Change in augmentation index over 1-year of treatment
|
Baseline and 12 months
|
The change in AIx@75 and PWV over 5-year of treatment
Time Frame: Baseline and 5-year
|
long term effect on vascular outcomes (including changes in PWV and AIx) after 5 years.
|
Baseline and 5-year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lai Shan Tam, MD, Chinese University of Hong Kong
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ERA-Alx-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Rheumatoid Arthritis
-
Societe Francaise de RhumatologieUniversity Hospital, Strasbourg, France; University Hospital, Rouen; University... and other collaboratorsActive, not recruitingEarly Rheumatoid Arthritis or Early Undiffentiated Arthritis
-
Federal University of São PauloCompletedEarly Rheumatoid Arthritis
-
AbbVie (prior sponsor, Abbott)CompletedEarly Rheumatoid ArthritisUnited States, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Slovakia, Spain, Sweden, Switzerland, United Kingdom
-
National Institute of Medical Sciences and Nutrition...RecruitingRheumatoid Arthritis | Early Rheumatoid ArthritisMexico
-
Chinese University of Hong KongCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.UnknownEarly Rheumatoid ArthritisChina
-
AbbVie (prior sponsor, Abbott)CompletedEarly Rheumatoid ArthritisUnited States, Argentina, Austria, Belgium, Canada, Czech Republic, Germany, Poland, Puerto Rico, Spain
-
University of ZurichUnknownErosive Disease in Early Rheumatoid Arthritis
-
Rottapharm BiotechCompletedRheumatoid Arthritis, DMARD-naive and Early Disease PatientsCzechia
-
Erasmus Medical CenterUMC Utrecht; Albert Schweitzer Hospital; Maasstad Hospital; Medical Center Alkmaar and other collaboratorsCompletedRheumatoid Arthritis | Predictive Value of Ultrasound in Early Rheumatoid ArthritisNetherlands
Clinical Trials on SDAI remission
-
Sint MaartenskliniekRecruiting
-
IWK Health CentreThe Hospital for Sick Children; Alberta Children's Hospital; Stollery Children...TerminatedPediatric Ulcerative Colitis | Pediatric Crohn's Disease
-
Shengjing HospitalCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
University of PittsburghCompletedMyositis | Dermatomyositis | PolymyositisUnited States
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Austrian Breast & Colorectal Cancer Study GroupPharmacia Austria GmbHCompletedBreast CancerAustria
-
Julia OttenRegion VästerbottenCompleted
-
Azienda Ospedaliero, Universitaria PisanaNot yet recruitingObesity | Diabetes Mellitus Type 2 in ObeseItaly